BREAKTHROUGH EFFECTIVE TREATMENT FOR DEPRESSION PATIENTS

Have Antidepressants Failed to Achieve Results for Your Patients?

Major Depressive Disorder has traditionally been treated with anti-depressants.

However, research demonstrates that anti-depressants have failed to achieve satisfactory results for many patients[1].

The patented breakthrough technology of Brainsway™ unfolds a new dawn in Depression treatment. The company offers a clinically-proven solution for various categories of Depression patients, ranging from mild to severe Depression cases, who failed to achieve sufficient outcomes from existing treatments in the current episode.

The treatment performs deep non-invasive brain stimulation using directed electromagnetic fields, thus rebalancing abnormal brain structures.

Brainsway's technology is based on patents filed by the U.S. National Institutes of Health (NIH) and the company. The treatment has been enthusiastically embraced by the international academic community, with over 60 clinical trials in leading institutions worldwide, and a wide variety of psychiatric and neurological indications.

Brainsway

Unrivaled Solution

Brainsway's solution stands matchless in its advantages, as traditional Depression treatments have been shown to be insufficient in terms of efficacy and also entail significant side effects[1].

Antidepressants, on top of their unsatisfactory response rates, entail systemic side effects leading many patients to neglect their medication regime. Other alternatives, such as Electroconvulsive Therapy (ECT), require anesthesia and involve significant risks and side effects, while Surface TMS (Transcranial Magnetic Stimulation) is more limited in its ability to stimulate deep cortical areas.

Therefore, in many cases, Depression patients have been virtually trapped in their condition with no adequate solutions.

Brainsway's novel dTMS (Deep Transcranial Magnetic Stimulation) technology holds a variety of benefits for Depression patients. In addition to its noninvasive stimulation of deep brain regions, resulting in high efficiency, the treatment involves no hospitalization, typically requiring only brief 20-minute daily sessions over a period of 4-5 weeks. Clinical trials that led to Brainsway's FDA clearance demonstrated excellent results in about half the average treatment time compared to existing TMS technology. Moreover, dTMS is safe, with no systemic effects and no long-term side effects. It is also highly convenient, as it can be administered in clinics of any size.

Clinically Proven, Certified and Safe

The FDA[2] and the CE have approved Brainsway dTMS for treatment of a wide range of patients, suffering from mild to severe and persistent Depression, who did not improve following the use of any number of antidepressants (in the current depressive episode).

The FDA indication is based on a unique long-term 16-week Double-Blind Placebo-Controlled Multi-Center study which enrolled over 230 subjects, showing a profound decline in HDRS-21 and significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study. In the study, Brainsway's treatment was proven to be safe, and the treatment was well tolerated by the majority of the study subjects.

Remission and Response Rates at Week 5*

* Remission – HDRS-21 Score < 10 ,
Response – Improvement of at least 50% from baseline

HDRS-21 Score Over Time



Slope (adjusted) of Change dTMS = -6.39 points
Slope (adjusted) of Change Sham = -3.28 points
P-value of Difference = 0.0080

[1] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006): Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 163:1905–1917.

[2] FDA 510(k) No. 122888

Brainsway

Brainsway and the Brainsway logo are trademarks of Brainsway Ltd.
© 2013 Brainsway. All Rights Reserved

For more information, scan the QR code
or visit **www.brainsway.com**.

Tel: 1-855-200-DTMS | **Email:** info@brainsway.com

BRO-0002-00-V2.0